DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM

GeorgeH Mccracken, DuaneL Dowell, FlorenceN Marshall

Research output: Contribution to journalArticle

16 Scopus citations

Abstract

130 infants with tetanus neonatorum were treated on a random basis with either 10,000 units of equine tetanus antitoxin (T.A.T.) or 500 units of human tetanus immune globulin (T.I.G.). 65 infants were in each treatment group. On the basis of mortality, and days in the hospital, days of gavage feeding, and days of sedation for the survivors, there was no significant difference in the treatment groups. The number and severity of complications were comparable for the two groups and no adverse reactions were observed in the 130 infants which could be attributed to either T.A.T. or T.I.G.

Original languageEnglish (US)
Pages (from-to)1146-1149
Number of pages4
JournalThe Lancet
Volume297
Issue number7710
DOIs
StatePublished - Jun 5 1971

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'DOUBLE-BLIND TRIAL OF EQUINE ANTITOXIN AND HUMAN IMMUNE GLOBULIN IN TETANUS NEONATORUM'. Together they form a unique fingerprint.

  • Cite this